Anesthesia, General Clinical Trial
Official title:
Computer-assisted Anaesthesia Using Pharmacokinetic/Pharmacodynamic Model
There are studies that suggest that unsatisfying levels of anesthesia can cause peri- and
postoperative complications in the patient undergoing surgery. Having a unnecessary "deep"
anesthesia level can be harmful, causing acute renal failure, injure to myocard, cause
delirium and increase the mortality rate. Being too "light", on the other hand, can make the
patient experience awareness when muscle relaxant is used. This can lead to serious
psychological struggles.
Evaluating the depth of anesthesia is the most important task of the anesthesia team, but can
be difficult because clinical signs depend on many factors. In addition to clinical
evaluation, EEG is commonly used for interpreting the level of anesthesia in todays practice.
Unfortunately, this method is not always accurate and has a delay.
New devices are now developed to calculate the anesthesia level based on the drugs given. The
level is simultaneously presented graphically on screen. The purpose of this study is to
investigate and compare clinical parameters within patients undergoing general anesthesia,
with and without the use of such devices. Hemodynamic stability, less use of adrenergics,
higher EEG-levels, a more rapid wake-up and shorter time in post operative care can indicate
a more precise level of anesthesia, hence, promote patient safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06063798 -
Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery
|
N/A | |
| Not yet recruiting |
NCT05035069 -
Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR
|
Phase 4 | |
| Completed |
NCT03861364 -
Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.
|
Phase 4 | |
| Completed |
NCT02711280 -
The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children
|
N/A | |
| Completed |
NCT01199471 -
Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
|
N/A | |
| Completed |
NCT00917033 -
Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy
|
Phase 4 | |
| Completed |
NCT00391885 -
Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy
|
Phase 4 | |
| Completed |
NCT00552617 -
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
|
Phase 2 | |
| Completed |
NCT03705026 -
Relationship Between Genetic Polymorphism and Postoperative Nausea and Vomiting in Chinese Han Population
|
||
| Completed |
NCT00552929 -
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
|
Phase 2 | |
| Completed |
NCT00298831 -
Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)
|
Phase 3 | |
| Completed |
NCT00475215 -
Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
|
Phase 3 | |
| Recruiting |
NCT03943745 -
EEG Changes During Induction of Propofol Anesthesia
|
||
| Completed |
NCT03697642 -
Nasopharyngeal Airway Guide Nasogastric Tube Placement
|
N/A | |
| Completed |
NCT04595591 -
Observation of Propofol Titration at Different Speeds
|
N/A | |
| Not yet recruiting |
NCT05841316 -
The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
|
||
| Completed |
NCT04532502 -
Impact of Anesthetic Environment the Sex Ratio of the Children of Female Assistants
|
||
| Completed |
NCT03330236 -
EEG - Guided Anesthetic Care and Postoperative Delirium
|
N/A | |
| Recruiting |
NCT06205212 -
High-flow Nasal Oxygenation During Preoxygenation and Atelectasis
|
N/A | |
| Completed |
NCT00379613 -
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
|
Phase 2 |